U.S. Food and Staples Retail Stock News

NasdaqGM:AGNT
NasdaqGM:AGNTReal Estate

AGNT Rebrands eXp With NextHome Acquisition And Multi Model Upside

eXp World Holdings, now trading under the ticker NasdaqGM:AGNT, has acquired franchise based brokerage NextHome. The company is shifting to a multi model real estate platform that offers both cloud brokerage and franchise options for agents and brokers. The new structure brings multiple brands under one global umbrella, with the AGNT ticker reflecting the broader platform focus. For real estate investors, NasdaqGM:AGNT now represents more than a pure cloud brokerage business. The...
NYSE:LXU
NYSE:LXUChemicals

What LSB Industries (LXU)'s Profit Rebound and Expansion Plans Mean For Shareholders

In late April 2026, LSB Industries, Inc. reported first-quarter sales of US$169.49 million and net income of US$19.69 million, reversing a loss a year earlier. Alongside this earnings improvement, management highlighted active review of debottlenecking projects and potential acquisitions or partnerships to expand fertilizer and industrial production capacity and gain scale. With earnings swinging to profit and management evaluating capacity-expanding investments, we’ll now examine how this...
NasdaqGS:MNST
NasdaqGS:MNSTBeverage

Three High ROE Stocks With Quietly Powerful Balance Sheets

Markets are wrestling with higher inflation, rising bond yields and volatile energy prices, so quality balance sheets matter more than ever. When borrowing costs and policy expectations shift frequently, companies with strong return on equity, resilient past performance and solid finances can give you cleaner exposure to long term growth stories, without relying on heavy leverage or speculative turnarounds. This article focuses on a curated screener that looks exactly for that mix of quality...
NYSE:AGBK
NYSE:AGBKBanks

Is AGI (AGBK) Offering A Rare Opportunity After A 34.8% Year To Date Slide?

Wondering whether AGI at around US$7.01 is a bargain or a value trap? This article walks through the key valuation clues that can help you frame that question. Over the last week the stock gained 2.9%, while over the past month it fell 1.3% and year to date it is down 34.8%. This naturally raises questions about how the market is currently pricing its prospects and risks. Recent coverage has focused on AGI's position in the US banking sector and how its share price has reacted to shifts in...
NYSE:ONON
NYSE:ONONLuxury

Lazard And 2 Stocks That May Be Trading Below Their Estimated Value

Over the last 7 days, the United States market has risen by 2.2%, contributing to a significant 31% increase over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for growth and diversification.
NasdaqGS:OPK
NasdaqGS:OPKHealthcare

Spotlight On Promising Penny Stocks For May 2026

Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.
NasdaqGS:MCBS
NasdaqGS:MCBSBanks

US Market's 3 Undiscovered Gems with Promising Potential

Over the last 7 days, the United States market has risen by 2.2%, contributing to a notable 31% increase over the past year, with earnings expected to grow by 17% annually in the coming years. In this thriving environment, identifying stocks with strong fundamentals and growth potential can be key to uncovering hidden opportunities within the market's landscape.
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Is It Too Late To Consider EyePoint (EYPT) After A 133% One-Year Surge?

Wondering whether EyePoint at US$13.66 still offers value after a big run, or whether most of the opportunity is already priced in. The stock is up 133.5% over the past year and 127.7% over three years, even though it has fallen 1.4% over the last week, 3.7% over the past month and 21.9% year to date. Recent market attention on EyePoint has focused on its position within the US pharmaceuticals and biotech space and how investors are reassessing risk across smaller healthcare stocks...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?

If you are wondering whether Amylyx Pharmaceuticals at US$14.73 is still offering value after a strong run, it helps to step back and look at what the price is really reflecting. The stock is up 29.0% year to date and 220.2% over the past year, even though it has fallen about 10.5% over the past week and 10.0% over the past month. These moves can change how you think about both opportunity and risk. Across financial media and industry commentary, recent attention has focused on Amylyx as a...
NYSE:BBU
NYSE:BBUIndustrials

A Look At Brookfield Business Partners (NYSE:BBU) Valuation After Softer Q1 Earnings And Recent Share Price Pullback

Q1 earnings and dividend decision put Brookfield Business Partners (NYSE:BBU) in focus Brookfield Business Partners (NYSE:BBU) is drawing attention after Brookfield Business Corporation reported first quarter 2026 results with lower sales and net income, alongside a fresh quarterly dividend declaration. For the quarter ended March 31, 2026, Brookfield Business Corporation reported sales of US$6,436 million, compared with US$6,749 million a year earlier, and net income of US$40 million,...